2020/06/02 by Adrian Heald, Mike Stedman, Mark Davies +5 · 1 voice · 2 citations
Medicine · #Chronic Disease Management Strategies #Diabetes Management and Education #Diabetes Management and Research
paper · doi:10.1097/xce.0000000000000210
openalex publication_date 2020/06/02 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28
With sustained growth of diabetes numbers, sustained patient engagement is essential. Using nationally available data, we have shown that the higher mortality associated with a diagnosis of T1DM/T2DM could produces loss of 6.4 million future life years in the current UK population. In the model, the 'average' person with T1DM (age 42.8 years) has a life expectancy from now of 32.6 years, compared to 40.2 years in the equivalent age non diabetes mellitus population, corresponding to lost life years (LLYs) of 7.6 years/average person. The 'average' person with T2DM (age 65.4 years) has a life expectancy from now of 18.6 years compared to the 20.3 years for the equivalent non diabetes mellitus population, corresponding to LLY of 1.7 years/average person. We estimate that for both T1DM and T2DM, one year with HbA1c >58 mmol/mol loses around 100 life days. Linking glycaemic control to mortality has the potential to focus minds on effective engagement with therapy and lifestyle recommendation adherence.